Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11981716 Activatable interleukin-2 polypeptides and methods of use thereof

Patent 11981716 was granted and assigned to Werewolf Therapeutics on May, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Werewolf Therapeutics
Werewolf Therapeutics
0
Date Filed
May 14, 2021
0
Date of Patent
May 14, 2024
0
Patent Applicant
Werewolf Therapeutics
Werewolf Therapeutics
0
Patent Application Number
17320779
0
Patent Citations
‌
US Patent 8734774 Protease activated cytokines
0
‌
US Patent 6942853 Latent fusion protein
0
‌
US Patent 7498298 Monomethylvaline compounds capable of conjugation to ligands
0
‌
US Patent 7514073 Therapeutic use of interleukin-2 mutants
0
‌
US Patent 8399219 Protease activatable interferon alpha proprotein
0
‌
US Patent 8563269 Modified antibody compositions, methods of making and using thereof
0
‌
US Patent 9856314 Activatable antibodies having non-binding steric moieties and methods of using the same
0
‌
US Patent 9861705 Conjugates of an IL-2 moiety and a polymer
0
‌
US Patent 9889211 Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
0
‌
US Patent 10059762 Anti-EGFR activatable antibodies
0
•••
Patent Inventor Names
Patrick Baeuerle
0
Heather Brodkin
0
Jose Andres Salmeron Garcia
0
Luke Evnin
0
William Winston
0
Daniel Hicklin
0
Vinay Bhaskar
0
Cynthia Seidel-Dugan
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11981716
0
Patent Primary Examiner
‌
Prema M Mertz
0
CPC Code
‌
C07K 14/55
0

Find more entities like US Patent 11981716 Activatable interleukin-2 polypeptides and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.